Cannabinoids and reduced risk of hepatic steatosis in HIV-HCV co-infection: paving the way for future clinical research - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue EXPERT REVIEW OF ANTI-INFECTIVE THERAPY Année : 2018

Cannabinoids and reduced risk of hepatic steatosis in HIV-HCV co-infection: paving the way for future clinical research

Dates et versions

hal-02146867 , version 1 (04-06-2019)

Identifiants

Citer

Fabienne Marcellin, Helene Fontaine, Lawrence Serfaty, Philippe Sogni, Patrizia M. Carrieri. Cannabinoids and reduced risk of hepatic steatosis in HIV-HCV co-infection: paving the way for future clinical research. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2018, 16 (5), pp.377-380. ⟨10.1080/14787210.2018.1473764⟩. ⟨hal-02146867⟩
25 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More